Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin

Inclusion Criteria

• •Women
• •over 18 years
• •Patient with locally or metastatic advanced breast cancer histologically documented who received at least one chemotherapy regimen that includes an anthracycline and a taxane unless in patients who can not receive these treatments
• •Patient to be treated with eribulin
• •Patient that should preventively receive granulocyte growth factors at the first cycle (patient who already experienced febrile neutropenia, patient with a low neutrophil count at baseline, patient with a Performance Status altered or any other condition requiring administration of granulocyte colony stimulating factor as recommended by the oncologist)
• •Neutrophils\> 1500 / mm3; platelets\> 100,000 / mm3
• •Dated and signed Informed consent
• •For patients of childbearing age, effective contraception during treatment and up to 3 months after stopping treatment